News | March 31, 2026
Kenvue unleashes science-driven skincare offensive at American Academy of Dermatology meet
The showcase, running March 27–31, puts a spotlight on everything from fine lines to daily sun protection
The showcase, running March 27–31, puts a spotlight on everything from fine lines to daily sun protection
The decision is based on the phase 3 DESTINY-Breast11 trial
The new assay consolidates screening for four major viral threats into a single workflow
Allergan also presented new insights on the growing population of patients on GLP-1 agonists for weight loss who are seeking aesthetic treatments
Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery
The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework
The inspection is now closed, and no regulatory action has been recommended
This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
KeyCi’s dermatologically tested lineup emphasizes clean formulations—vegan, cruelty-free, alcohol-free, and paraben-free—while being backed by pharmaceutical-grade research and FDA approval
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
